ClinicalTrials.gg
CompletedNCT01928368Updated Dec 14, 2016

A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.

A Phase 1 interventional study of AMG 282 and AMG 282 Matching Placebo in Asthma, sponsored by Amgen. Completed at 5 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-12-14.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Asthma by Amgen — none open to participants now, 2 under way, none of them phase 3. Asthma · Amgen.

Enrollment
6th of 13
70 · median 31
Started
2013
with 1 other
Phase 1
7 of 13
none open now
Registered
10th of 13
by date

Among the 13 studies in Asthma by Amgen, this one is the 6th largest by enrollment, is one of 2 that started in 2013, is one of 7 in phase 1, and was the 10th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 13 studies in Asthma by Amgen is open now. The open studies under Asthma, anywhere →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Asthma by Amgen as a file.
02

Study summary

The purpose of this study is to determine if a single dose of AMG 282 is safe in healthy subjects and subjects with mild atopic asthma.

Read the detailed description

A single SC or IV dose administration of AMG 282 to healthy subjects and subjects with mild atopic asthma will exhibit an acceptable safety and tolerability profile within the dose ranges studied.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Mild asthma
  • Atopic asthma
  • Healthy volunteers
  • First-in-human
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is a current non-smoker, has not used any nicotine or tobacco containing products (including but not limited to: snuff, chewing tobacco, cigars, cigarettes, pipes, or nicotine patches) within the last 6 months, and cumulative smoking history is ≤10 pack years.
  • Females must be of documented non- (ie, [see definition below]; OR history of hysterectomy; OR history of bilateral salpingectomy; OR history of bilateral oophorectomy).
  • (BMI) between ≥ 18.0 and ≤ 32.0 kg/m2 at screening. (Subjects with mild atopic asthma only)
  • Documented history of mild, stable atopic asthma within 2 years of screening.
  • Has used only inhaled short-acting β2-agonists (less than twice weekly) to treat asthma.
  • Pre-bronchodilator (FEV1) > 70% predicted at screening.

Exclusion criteria

Exclusion Criteria

(All subjects)

  • History or evidence of a disorder, condition or disease that, in the opinion of the Principal Investigator or Amgen medical monitor would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.
  • Subject has a history of residential exposure to tuberculosis without a documented history of prophylactic treatment of tuberculosis or subject has a positive purified protein derivative (PPD) or QuantiFERON test at screening. Subjects with a documented negative PPD or QuantiFERON test within 4 weeks prior to screening who have no known tuberculosis exposure and have not traveled to an area with tuberculosis do not need to have a test performed at screening.
  • Has donated or lost ≥ 500 mL of blood or plasma within 8 weeks of administration of the first dose of IP.

Other criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Active comparator
    Experimental Arm

    Drug: AMG 282

  • Placebo comparator
    Placebo Arm

    Drug: AMG 282 Matching Placebo

Interventions

  • Single dose either subcutaneously or intravenously on day 1.

  • DrugAMG 282 Matching Placebo

    Single dose of matching AMG 282 placebo either subcutaneously or intravenously on day 1.

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent adverse events

    Time frame: Up to day 141

  2. Incidence of abnormal clinically significant vital signs

    Time frame: Up to day 141

  3. Incidence of abnormal clinically significant chemistry, hematology and urinalysis test results

    Time frame: Up to day 141

  4. Incidence of abnormal clinically significant ECG results

    Time frame: Up to day 141

  5. Incidence of anti-AMG 282 antibodies

    Time frame: Up to 1 year

Secondary outcomes

  1. Determination of various PK parameters including tmax, AUClast and Cmax

    Time frame: Up to day 141

Other outcomes

  1. Measurement of various pharmacodynamic biomarkers in subjects with mild atopic asthma

    Time frame: Up to day 141

07

Study locations

5 sites
  • Research Site
    Cypress, California 90630, United States
  • Research Site
    Aventura, Florida 33180, United States
  • Research Site
    Lenexa, Kansas 66219, United States
  • Research Site
    Raleigh, North Carolina 27612, United States
  • Research Site
    Seattle, Washington 98115, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2013
First posted
Aug 23, 2013
Start
Aug 2013
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Last update
Dec 14, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01928368
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 23, 2013
Start date
Aug 2013
Primary completion
Mar 2016
Completion
Mar 2016
Last update
Dec 14, 2016

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Astegolimab

Start the discussion